Dyne Therapeutics IncNASDAQ:DYN
- LAST PRICE32.1900
- TODAY'S CHANGE (%)0.7800 (2.4833%)
- Bid / Lots32.1500/ 1
- Ask / Lots32.2000/ 10
- Open / Previous Close31.6200 / 31.4100
- Day Range
- 52 Week Range
- Volume393,302
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DYN |
|---|---|---|
| 09:32 ET | 4809 | 31.44 |
| 09:34 ET | 600 | 31.43 |
| 09:38 ET | 159 | 31.5255 |
| 09:41 ET | 3123 | 31.8 |
| 09:45 ET | 6516 | 31.72 |
| 09:48 ET | 1118 | 31.64 |
| 09:52 ET | 300 | 31.44 |
| 09:54 ET | 1100 | 31.55 |
| 09:57 ET | 500 | 31.42 |
| 09:59 ET | 100 | 31.475 |
| 10:01 ET | 3898 | 31.65 |
| 10:03 ET | 1280 | 31.53 |
| 10:06 ET | 200 | 31.565 |
| 10:08 ET | 669 | 31.45 |
| 10:10 ET | 400 | 31.37 |
| 10:12 ET | 1252 | 31.21 |
| 10:14 ET | 1200 | 31.24 |
| 10:15 ET | 1212 | 31.14 |
| 10:17 ET | 300 | 31.17 |
| 10:19 ET | 800 | 31.3 |
| 10:21 ET | 400 | 31.425 |
| 10:24 ET | 300 | 31.59 |
| 10:26 ET | 225 | 31.6421 |
| 10:28 ET | 14528 | 31.58 |
| 10:30 ET | 500 | 31.58 |
| 10:32 ET | 1100 | 31.51 |
| 10:33 ET | 1686 | 31.6 |
| 10:35 ET | 1882 | 31.72 |
| 10:37 ET | 400 | 31.72 |
| 10:39 ET | 600 | 31.74 |
| 10:42 ET | 3317 | 31.785 |
| 10:44 ET | 800 | 31.77 |
| 10:46 ET | 1986 | 31.87 |
| 10:48 ET | 499 | 31.92 |
| 10:50 ET | 2400 | 31.93 |
| 10:53 ET | 1075 | 31.98 |
| 10:55 ET | 17072 | 31.8 |
| 10:57 ET | 817 | 31.69 |
| 11:00 ET | 2245 | 31.75 |
| 11:02 ET | 1803 | 31.79 |
| 11:04 ET | 700 | 31.83 |
| 11:06 ET | 200 | 31.83 |
| 11:08 ET | 200 | 31.81 |
| 11:09 ET | 300 | 31.77 |
| 11:11 ET | 1400 | 31.77 |
| 11:13 ET | 2096 | 31.67 |
| 11:15 ET | 12537 | 31.76 |
| 11:18 ET | 900 | 31.805 |
| 11:20 ET | 1368 | 31.795 |
| 11:22 ET | 1500 | 31.87 |
| 11:24 ET | 713 | 31.96 |
| 11:26 ET | 66749 | 31.92 |
| 11:27 ET | 400 | 31.9 |
| 11:29 ET | 200 | 31.87 |
| 11:31 ET | 100 | 31.86 |
| 11:33 ET | 1100 | 31.97 |
| 11:36 ET | 880 | 31.94 |
| 11:38 ET | 100 | 31.91 |
| 11:40 ET | 1133 | 31.92 |
| 11:42 ET | 2362 | 31.955 |
| 11:44 ET | 18143 | 32 |
| 11:45 ET | 18710 | 31.98 |
| 11:49 ET | 5465 | 31.985 |
| 11:51 ET | 2041 | 31.99 |
| 11:54 ET | 200 | 31.975 |
| 11:56 ET | 25470 | 32.155 |
| 11:58 ET | 300 | 32.155 |
| 12:00 ET | 2872 | 32.105 |
| 12:02 ET | 900 | 32.1809 |
| 12:03 ET | 930 | 32.125 |
| 12:05 ET | 295 | 32.13 |
| 12:09 ET | 100 | 32.19 |
| 12:12 ET | 902 | 32.15 |
| 12:14 ET | 981 | 32.2 |
| 12:16 ET | 200 | 32.18 |
| 12:18 ET | 200 | 32.15 |
| 12:20 ET | 3142 | 32.15 |
| 12:21 ET | 14577 | 32.1 |
| 12:23 ET | 1330 | 32.085 |
| 12:25 ET | 1500 | 32.03 |
| 12:27 ET | 200 | 32.03 |
| 12:30 ET | 394 | 32.15 |
| 12:32 ET | 6053 | 32.255 |
| 12:34 ET | 885 | 32.34 |
| 12:36 ET | 1300 | 32.34 |
| 12:38 ET | 10875 | 32.255 |
| 12:39 ET | 1475 | 32.31 |
| 12:41 ET | 400 | 32.2878 |
| 12:43 ET | 100 | 32.31 |
| 12:45 ET | 250 | 32.32 |
| 12:48 ET | 972 | 32.305 |
| 12:52 ET | 200 | 32.31 |
| 12:54 ET | 950 | 32.285 |
| 12:56 ET | 200 | 32.3 |
| 12:57 ET | 424 | 32.3 |
| 12:59 ET | 2098 | 32.27 |
| 01:01 ET | 3004 | 32.13 |
| 01:03 ET | 890 | 32.08 |
| 01:06 ET | 500 | 32.095 |
| 01:10 ET | 500 | 32.1 |
| 01:12 ET | 400 | 32.14 |
| 01:14 ET | 100 | 32.15 |
| 01:15 ET | 355 | 32.2386 |
| 01:19 ET | 430 | 32.19 |
| 01:21 ET | 300 | 32.19 |
May 30, 2024
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference, from 7:30AM ET on Thursday May 30, 2024 by Dow Jones
7:30AM ET on Thursday May 30, 2024 by Dow Jones
May 28, 2024
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow Jones
May 21, 2024
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock, from 8:39PM ET on Tuesday May 21, 2024 by Dow Jones
8:39PM ET on Tuesday May 21, 2024 by Dow JonesDJ Dyne Therapeutics Is Maintained at Buy by Chardan Capital, from 8:26AM ET on Tuesday May 21, 2024 by Dow Jones
8:26AM ET on Tuesday May 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dyne Therapeutics Inc | 3.1B | -8.1x | --- |
Biohaven Ltd | 3.1B | -5.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.0x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
Janux Therapeutics Inc | 2.8B | -38.2x | --- |
Company Information
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Contact Information
- Headquarters
- 1560 Trapelo RoadWALTHAM, MA, United States 02451
- Phone
- 781-786-8230
- Fax
- 781-786-8866
Executives
- Independent Chairman of the Board
- Jason Rhodes
- President, Chief Executive Officer, Director
- John Cox
- Chief Operating Officer
- Susanna High
- Senior Vice President, Head of Finance and Administration
- Richard Scalzo
- Chief Scientific Officer
- Oxana Beskrovnaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 97.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-3.97 |
Book Value | $1.49 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
